Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 10 » Issue 1

Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch

Authors Hanada S, Wada S, Ohno T, Sawaguchi H, Muraki M, Tohda Y

Received 30 August 2014

Accepted for publication 27 November 2014

Published 6 January 2015 Volume 2015:10(1) Pages 69—77

DOI https://doi.org/10.2147/COPD.S73521

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Dr Richard Russell

Soichiro Hanada,1 Shota Wada,1 Takeshi Ohno,1 Hirochiyo Sawaguchi,1 Masato Muraki,1 Yuji Tohda2

1Department of Respiratory Medicine and Allergology, Nara Hospital, Kinki University Faculty of Medicine, Ikoma, 2Department of Respiratory Medicine and Allergology, Kinki University Faculty of Medicine, Osakasayama, Japan


Background: Tiotropium (Spiriva) is an inhaled muscarinic antagonist for patients with chronic obstructive pulmonary disease (COPD), and is available in two forms: the HandiHaler and the Respimat inhaler. The aim of this study was to investigate the handling of and preference for each device immediately after switching from the HandiHaler to the Respimat and 2–3 years after the switch.
Materials and methods: The study comprised two surveys. A questionnaire was first administered to 57 patients with COPD (male:female 52:5, mean age 73.6±7.1 years) 8 weeks after switching from the HandiHaler (18 µg) to the Respimat (5 µg). A second similar but simplified questionnaire was administered to 39 of these patients who continued to use the Respimat and were available for follow-up after more than 2 years. Pulmonary function was also measured during each period.
Results: In the first survey, 17.5% of patients preferred the HandiHaler, and 45.6% preferred the Respimat. There were no significant changes in pulmonary function or in the incidence of adverse events after the switch. In the second survey, performed 2–3 years later, the self-assessed handling of the Respimat had significantly improved, and the number of patients who preferred the Respimat had increased to 79.5%.
Conclusion: The efficacy of the Respimat was similar to that of the HandiHaler. This was clear immediately after the switch, even in elderly patients with COPD who were long-term users of the HandiHaler. The preference for the Respimat increased with continued use.

Keywords: chronic obstructive pulmonary disease, tiotropium, HandiHaler, Respimat, questionnaire, pulmonary function

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Readers of this article also read:

Patient preferences in severe COPD and asthma: a comprehensive literature review

Bereza BG, Troelsgaard Nielsen A, Valgardsson S, Hemels MEH, Einarson TR

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:739-744

Published Date: 8 April 2015

Home-based pulmonary rehabilitation improves clinical features and systemic inflammation in chronic obstructive pulmonary disease patients

Nascimento ESP, Sampaio LMM, Peixoto-Souza FS, Dias FD, Gomes ELFD, Greiffo FR, Ligeiro de Oliveira AP, Stirbulov R, Vieira RP, Costa D

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:645-653

Published Date: 23 March 2015

Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease

Nishijima Y, Minami S, Yamamoto S, Ogata Y, Koba T, Futami S, Komuta K

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:439-444

Published Date: 27 February 2015

The effect of comorbidities on COPD assessment: a pilot study

Weinreich UM, Thomsen LP, Bielaska B, Jensen VH, Vuust M, Rees SE

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:429-438

Published Date: 25 February 2015

Long-term efficacy of intensive cycle ergometer exercise training program for advanced COPD patients

Pothirat C, Chaiwong W, Phetsuk N, Liwsrisakun C, Bumroongkit C, Deesomchok A, Theerakittikul T, Limsukon A

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:133-144

Published Date: 12 January 2015

Managing comorbidities in COPD

Hillas G, Perlikos F, Tsiligianni I, Tzanakis N

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:95-109

Published Date: 7 January 2015

Knowledge about COPD among users of primary health care services

Queiroz MC, Moreira MA, Jardim JR, Barbosa MA, Minamisava R, Gondim HD, Velasco FC, Penhavel MV

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1-6

Published Date: 17 December 2014

Lobar analysis of collapsibility indices to assess functional lung volumes in COPD patients

Kitano M, Iwano S, Hashimoto N, Matsuo K, Hasegawa Y, Naganawa S

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1347-1356

Published Date: 9 December 2014